| Nome |
# |
|
Knowledge of sexually transmitted infections and risky behaviours: a survey among high school and university students, file de3e52b3-6665-762d-e053-3705fe0a30e0
|
175
|
|
null, file de3e52b2-1930-762d-e053-3705fe0a30e0
|
81
|
|
Factors Associated With Weight Gain in People Treated With Dolutegravir, file de3e52b3-6101-762d-e053-3705fe0a30e0
|
65
|
|
Sinus bradycardia in a patient with bacterial meningitis in therapy with IVIg: a case report, file de3e52b2-1a73-762d-e053-3705fe0a30e0
|
57
|
|
Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review, file de3e52b1-7a0f-762d-e053-3705fe0a30e0
|
48
|
|
Kaposi’s sarcoma in HIV-infected patients in the era of new antiretrovirals, file de3e52b3-a72c-762d-e053-3705fe0a30e0
|
38
|
|
Prostate cancer in HIV-positive patients: a review of the literature, file de3e52b1-9f9b-762d-e053-3705fe0a30e0
|
37
|
|
Comparative neuropsychiatric toxicity profile of dolutegravir versus efavirenz versus other antiretroviral third drugs used either in first-line or switching antiretroviral therapies (ART): data from ICONA Foundation Study Cohort, file de3e52b2-2e23-762d-e053-3705fe0a30e0
|
37
|
|
Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients., file de3e52b3-762c-762d-e053-3705fe0a30e0
|
32
|
|
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project, file de3e52b1-070e-762d-e053-3705fe0a30e0
|
30
|
|
Unusual Signs and Symptoms in HIV-Positive Patients Coinfected with Leishmania spp: The Importance of Neglected Tropical Disease in Differential Diagnosis, file de3e52b3-55f3-762d-e053-3705fe0a30e0
|
30
|
|
Dolutegravir tolerability in clinical practice: results from the SCOLTA cohort, file de3e52b1-9193-762d-e053-3705fe0a30e0
|
23
|
|
null, file de3e52b1-b772-762d-e053-3705fe0a30e0
|
23
|
|
Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort, file de3e52b4-7d3b-762d-e053-3705fe0a30e0
|
23
|
|
Breast cancer in women living with HIV, file de3e52b1-cf71-762d-e053-3705fe0a30e0
|
22
|
|
Anal cancer in people living with HIV: the importance of the screening and of early diagnosis, file de3e52b2-0ecd-762d-e053-3705fe0a30e0
|
20
|
|
Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review)., file de3e52b3-3652-762d-e053-3705fe0a30e0
|
20
|
|
Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort, file de3e52b2-0485-762d-e053-3705fe0a30e0
|
19
|
|
Bacteremic meningitis due to Pasteurella multocida resistant to first line antibiotic therapy, file de3e52b3-2c87-762d-e053-3705fe0a30e0
|
19
|
|
EDITORIAL – IMPROVING ACCESS AND ADHERENCE TO SCREENING TESTS FOR CANCERS: A NEW, THOUGH OLD, CHALLENGE IN THE HIV EPIDEMICS, file de3e52b1-830e-762d-e053-3705fe0a30e0
|
18
|
|
Pseudomonas aeruginosa detection in South Italy: an epidemiological survey, file de3e52b1-b41e-762d-e053-3705fe0a30e0
|
18
|
|
Circulating angiopoietin‑like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease, file de3e52b3-5c48-762d-e053-3705fe0a30e0
|
17
|
|
Durability of F/TAF-based regimens in a large cohort of PLWH seen of care in Italy, file de3e52b3-7c3f-762d-e053-3705fe0a30e0
|
17
|
|
Awareness and perception of accurancy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA), in Italy and correlation with the level of confidence in reference physicians., file de3e52b3-c874-762d-e053-3705fe0a30e0
|
15
|
|
Comparative neuropsychiatric toxicity profile of dolutegravir (DGT)-based versus efavirenz (EFV)-based versus other recommend first-line antiretroviral therapies (ART): data from ICONA Foundation Study Cohort., file de3e52b2-03e4-762d-e053-3705fe0a30e0
|
14
|
|
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudina/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients., file de3e52b3-5da9-762d-e053-3705fe0a30e0
|
14
|
|
Kaposi’s sarcoma in HIV-infected patients in the era of new antiretrovirals, file de3e52b3-a72d-762d-e053-3705fe0a30e0
|
14
|
|
Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients., file de3e52b3-a72e-762d-e053-3705fe0a30e0
|
14
|
|
Kaposi’s sarcoma in HIV-infected patients in the era of new antiretrovirals, file de3e52b3-762b-762d-e053-3705fe0a30e0
|
13
|
|
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and hepatic safety: a new paradigm?, file de3e52b4-3c97-762d-e053-3705fe0a30e0
|
12
|
|
Outbreak of Brucella melitensis infection in Eastern Sicily: risk factors, clinical characteristics and complication rate, file de3e52b1-ce56-762d-e053-3705fe0a30e0
|
11
|
|
Pre-ART HIV-1 DNA in CD4! T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART, file de3e52b3-f345-762d-e053-3705fe0a30e0
|
11
|
|
Dolutegravir tolerability in clinical practice: results from the SCOLTA cohort, file de3e52b4-0f00-762d-e053-3705fe0a30e0
|
11
|
|
Effectiveness of dolutegravir-based regimens as either first-line orswitch antiretroviral therapy: data from the Icona cohort, file de3e52b1-c902-762d-e053-3705fe0a30e0
|
10
|
|
Is the rate of virological failure to cART continuing to decline in recent calendar years?, file de3e52b2-0350-762d-e053-3705fe0a30e0
|
10
|
|
Impact of multi-drug resistance on mortality: a multi-cohort Italian study., file de3e52b3-89bf-762d-e053-3705fe0a30e0
|
10
|
|
Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort, file de3e52b3-a9df-762d-e053-3705fe0a30e0
|
10
|
|
Vitamin D Status Modulates Inflammatory Response in HIV+ Subjects: Evidence for Involvement of Autophagy and TG2 Expression in PBMC, file de3e52b3-b6ac-762d-e053-3705fe0a30e0
|
10
|
|
null, file de3e52b2-0a47-762d-e053-3705fe0a30e0
|
9
|
|
Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up, file de3e52b2-b249-762d-e053-3705fe0a30e0
|
9
|
|
Epidemiology of the new HIV infections in a large university hospital of Southern Italy: the importance of increasing the culture of the HIV screening test in the prevention of late diagnosis, file de3e52b3-720f-762d-e053-3705fe0a30e0
|
9
|
|
Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients., file de3e52b3-b68b-762d-e053-3705fe0a30e0
|
9
|
|
HIV associated psoriasis: epidemiology, pathogenesis and management, file de3e52b1-f0c1-762d-e053-3705fe0a30e0
|
8
|
|
null, file de3e52b2-10da-762d-e053-3705fe0a30e0
|
8
|
|
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project, file de3e52b2-14fd-762d-e053-3705fe0a30e0
|
8
|
|
Factors associated with hospital admission for COVID-19 in HIV patients., file de3e52b3-865b-762d-e053-3705fe0a30e0
|
8
|
|
Efficacy and safety of boosted atazanavir-containig antiretroviral regimens in real life: results from a multicentre color study., file de3e52b1-a4a7-762d-e053-3705fe0a30e0
|
7
|
|
null, file de3e52b2-0a44-762d-e053-3705fe0a30e0
|
7
|
|
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudina/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients., file de3e52b2-161b-762d-e053-3705fe0a30e0
|
7
|
|
Epstein Barr Virus related cancer in people living with HIV: a review of the literature, file de3e52b2-74b1-762d-e053-3705fe0a30e0
|
7
|
|
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen, file de3e52b3-a7f9-762d-e053-3705fe0a30e0
|
7
|
|
New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection, file de3e52b3-c22c-762d-e053-3705fe0a30e0
|
7
|
|
null, file de3e52b4-7edb-762d-e053-3705fe0a30e0
|
7
|
|
Is there a relation between myalgia and central nervous system symptoms in patients receiving Raltegravir? Results from the Scolta Project., file de3e52ae-e74a-762d-e053-3705fe0a30e0
|
6
|
|
null, file de3e52b2-0538-762d-e053-3705fe0a30e0
|
6
|
|
null, file de3e52b2-0d93-762d-e053-3705fe0a30e0
|
6
|
|
Bone safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-Word Cohort., file de3e52b3-315b-762d-e053-3705fe0a30e0
|
6
|
|
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study-authors' response, file 4b4bd46f-4456-472e-bdef-a84886232c54
|
5
|
|
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex, file 78b855b6-cb54-49e4-adc6-16985086a873
|
5
|
|
96 Week Follow-Up of HIV-Infected Patients in Rescuewith Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience, file de3e52ae-e652-762d-e053-3705fe0a30e0
|
5
|
|
Bone marrow biopsy findings in brucellosis patients with hematologic abnormalities: useful remarks., file de3e52ae-f856-762d-e053-3705fe0a30e0
|
5
|
|
Weight gain in dolutegravir containing regimens in the observational
SCOLTA cohort., file de3e52b1-de5e-762d-e053-3705fe0a30e0
|
5
|
|
Editorial - Coronavirus disease 2019 and people living with HIV: clinical considerations, file de3e52b3-1d10-762d-e053-3705fe0a30e0
|
5
|
|
Definition of a novel vaccination pathway in PLWHA: experience of a Southern University Hospital, file de3e52b3-769e-762d-e053-3705fe0a30e0
|
5
|
|
Epidemiologia delle farmacoresistenze di HIV nella regione Sicilia, file de3e52b3-8d1c-762d-e053-3705fe0a30e0
|
5
|
|
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile, file de3e52b3-c8c8-762d-e053-3705fe0a30e0
|
5
|
|
Prevalence of HLA-B 5701 and access to genetic test in Sicily. A multicenter study., file de3e52ae-bf26-762d-e053-3705fe0a30e0
|
4
|
|
Anxiety disorders and adherence to HAART, file de3e52ae-bf29-762d-e053-3705fe0a30e0
|
4
|
|
Analisis of efficacy and tolerability of raltegravir based regimens by background therapy in salvage: a Mulcicentre Italian Experience., file de3e52ae-e749-762d-e053-3705fe0a30e0
|
4
|
|
null, file de3e52ae-f84f-762d-e053-3705fe0a30e0
|
4
|
|
Metabolic, renal and liver events related to EVG/COBI/FTC/TDF use in SCOLTA project: a real life experience, file de3e52b1-0710-762d-e053-3705fe0a30e0
|
4
|
|
HPV AND URINARY BLADDER CARCINOMA: A REVIEW OF THE LITERATURE, file de3e52b1-8310-762d-e053-3705fe0a30e0
|
4
|
|
Once-a-day (QD) vs. twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction, file de3e52b2-1b6d-762d-e053-3705fe0a30e0
|
4
|
|
Predictors of severe weight gain in patients treated with Dolutegravir, file de3e52b2-4764-762d-e053-3705fe0a30e0
|
4
|
|
Malignant melanoma in HIV: epidemiology, pathogenesis and management, file de3e52b2-7b42-762d-e053-3705fe0a30e0
|
4
|
|
Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients., file de3e52b3-20f5-762d-e053-3705fe0a30e0
|
4
|
|
Incidence and risk factors for liver enzyme elevation among naïve HIV-1 infected patients receiving ART in the ICONA cohort, file de3e52b3-5c46-762d-e053-3705fe0a30e0
|
4
|
|
null, file de3e52b4-604b-762d-e053-3705fe0a30e0
|
4
|
|
null, file de3e52b4-da03-762d-e053-3705fe0a30e0
|
4
|
|
Anxiety disorders and adherence to HAART, file de3e52ae-cca9-762d-e053-3705fe0a30e0
|
3
|
|
Efficacy of 1998 vs 2006 first-line antiretroviral regimens for HIV infection: an ordinary clinics retrospective investigation., file de3e52ae-e85b-762d-e053-3705fe0a30e0
|
3
|
|
New and old assumptions of lung cancer in people living with HIV, file de3e52b1-7a11-762d-e053-3705fe0a30e0
|
3
|
|
Pre-ART HIV-1 DNA in CD4! T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART, file de3e52b1-97cf-762d-e053-3705fe0a30e0
|
3
|
|
null, file de3e52b1-bab7-762d-e053-3705fe0a30e0
|
3
|
|
Incidence of dyslipidemia and modification of atherosclerotic cardiovascular disease (ASCVD) risk in HIV-infected patients who switch away from tenofovir disoproxil fumarato (TDF)-based to TDF-sparing regimens in the ICONA Foundation Cohort, file de3e52b2-048f-762d-e053-3705fe0a30e0
|
3
|
|
Hodgkin's Lymphoma in People Living with HIV: epidemiology and clinical management., file de3e52b2-0566-762d-e053-3705fe0a30e0
|
3
|
|
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project, file de3e52b2-05d4-762d-e053-3705fe0a30e0
|
3
|
|
null, file de3e52b2-0e38-762d-e053-3705fe0a30e0
|
3
|
|
null, file de3e52b2-10d6-762d-e053-3705fe0a30e0
|
3
|
|
Long-term follow-up of HIV-HBV co-infected patients according to the use of anti-HBV active drugs, file de3e52b2-10d8-762d-e053-3705fe0a30e0
|
3
|
|
Efficacy, safety and tolerability of dolutegravir-based combination antiretroviral therapy in clinical practice in HIV-infected patients: results from a multicenter study, file de3e52b2-50a8-762d-e053-3705fe0a30e0
|
3
|
|
null, file de3e52b2-5121-762d-e053-3705fe0a30e0
|
3
|
|
null, file de3e52b2-67d9-762d-e053-3705fe0a30e0
|
3
|
|
Bone disease in HIV infection: an overview of pathogenesis, clinical manifestations and treatment, file de3e52b2-7da6-762d-e053-3705fe0a30e0
|
3
|
|
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort, file de3e52b2-acb5-762d-e053-3705fe0a30e0
|
3
|
|
Non-AIDS defining cancers: a comprehensive update on diagnosis and management, file de3e52b2-b948-762d-e053-3705fe0a30e0
|
3
|
|
null, file de3e52b3-6121-762d-e053-3705fe0a30e0
|
3
|
|
HBcAb positivity increases the risk of severe hepatic fibrosis development in HIV-HCV-positive subjects from the ICONA Italian cohort of HIV-infected patients, file de3e52b3-7cf3-762d-e053-3705fe0a30e0
|
3
|
|
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected in individuals with viral load <=50 copies/ml: does eGFR matter?, file de3e52b3-a00b-762d-e053-3705fe0a30e0
|
3
|
|
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study, file de3e52b4-d868-762d-e053-3705fe0a30e0
|
3
|
| Totale |
1.349 |